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ABSTRACT
Objectives: Low-income women have high rates of smoking
during pregnancy, but little is known about the costs, ben-
eﬁts, and cost-effectiveness of motivational interviewing
(MI), focused on the medical and psychosocial needs of this
population, as an intervention for smoking cessation and
relapse prevention.
Methods: A sample of 302 low-income pregnant women was
recruited from multiple obstetrical sites in the Boston metro-
politan area into a randomized controlled trial of a motiva-
tional intervention for smoking cessation and relapse
prevention versus usual care (UC). The ﬁndings of this clini-
cal trial were used to estimate the costs, beneﬁts, and cost-
effectiveness of the intervention from a societal perspective,
incorporating published quality-adjusted life-year (QALY)
and life-year (LY) estimates. Outcomes included smoking
cessation and relapse, maternal and infant outcomes, eco-
nomic costs, LYs and QALYs saved, and incremental cost-
effectiveness ratios.
Results: The cost-effectiveness of MI for relapse prevention
compared to UC was estimated to be $851/LY saved and
$628/QALY saved. Including savings in maternal medical
costs in sensitivity analyses resulted in cost savings for MI for
relapse prevention compared to UC. For smoking cessation,
MI cost more but did not provide additional beneﬁt compared
to UC. In one-way sensitivity analyses, the incremental cost-
effectiveness of MI versus UC would have been $117,100/LY
saved and $86,300/QALY saved if 8% of smokers had quit. In
two-way sensitivity analyses, MI was still relatively cost-
effective for relapse prevention ($17,300/QALY saved) even if
it cost asmuch as $2000/participant andwas less effective. For
smoking cessation, however, a higher level of effectiveness
(9/110) and higher cost ($400/participant) resulted in higher
incremental cost-effectiveness ratios ($112,000/QALY).
Conclusions: Among low-income pregnant women, MI
helps prevent relapse at relatively low cost, and may be
cost-saving when net medical cost savings are considered. For
smoking cessation, MI cost more but provided no additional
beneﬁt compared to UC, but might offer beneﬁts at costs
comparable to other clinical preventive interventions if
8–10% of smokers are induced to quit.
Keywords: cost-effectiveness, low-income, pregnant women,
relapse prevention, smoking cessation.
Introduction
Smoking during and after pregnancy is associated with
adverse maternal and infant health outcomes [1] and
an increased risk of nicotine dependence among off-
spring [2]. Nevertheless, only about one-third of
female smokers quit when they become pregnant
(spontaneous quitters) [3], and rates are lower among
unmarried, low-income, poorly educated, non-
Hispanic white, or American Indian women, and
heavy smokers [1,4–6]. In 1998, 26% of women who
did not complete high school smoked during preg-
nancy versus 2% of women with a college degree [1].
Furthermore, for women who smoke but quit at some
time during pregnancy, relapse rates range from 70%
to 85%, stressing the difﬁculty in preventing relapse
during pregnancy and in the postpartum period [7].
Traditional cessation counseling—brief, low-
intensity interventions—offer modest beneﬁts to preg-
nant clients [8–17]. To our knowledge, no published
studies have estimated clinical beneﬁts in terms of life-
years (LYs) and quality-adjusted life-years (QALYs)
saved when low-income pregnant women quit smoking
and continue to abstain; nor have cost-effectiveness
analyses been performed for these interventions in this
target population as recommended by the US Panel on
Cost-Effectiveness in Health and Medicine [18].
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Factors that are associated with smoking during
and post pregnancy include a lack of awareness of fetal
damage, heavy smoking before pregnancy, being in a
relationship with a smoker, low self-efﬁcacy, and not
breast-feeding [12–14]. Traditional smoking cessation
and relapse prevention programs are also difﬁcult to
implement among lower-income populations because
of social and environmental factors.
We conducted a randomized, controlled trial and
cost-effectiveness analysis of individually tailored
motivational interviewing (MI), which public health
nurses delivered to low-income women. This client-
centered technique explores perceptions and concerns
about smoking, clariﬁes conﬂicting motivations,
focuses on the social context in which women live, and
provides support and skills of training. It also aims to
reduce household levels of nicotine, increase readiness
to quit, and lower relapse rates.
This study extends previous economic studies of
smoking cessation and relapse prevention during and
after pregnancy by examining a speciﬁc patient sub-
group, including microcosts of the programs, estimat-
ing costs per LYs and QALYs saved, and following
recommendations from the US Panel on Cost-
Effectiveness in Health and Medicine [18]. We devel-
oped a model for examining the cost-effectiveness of
MI as compared to usual care (UC) for low-income
pregnant women. The model is represented as a deci-
sion tree in Figure 1. The effectiveness and cost-
effectiveness of MI were evaluated separately for two
groups of women: current smokers (smoking cessa-
tion: SC) or recent quitters (relapse prevention: RP) at
baseline. We examined the cost-effectiveness analysis
(CEA) of the intervention for each of these groups
separately.
Methods
Recruitment, Design, and Sample
Participants were recruited by several hospital and
health clinics that deliver obstetrical care in the Boston
metropolitan area. Eligibility criteria included: 1)
being pregnant for less than 28 weeks and receiving
prenatal care at a participating site; 2) being a current
smoker (smoking cessation) or having been a smoker
within 3 months of baseline (relapse prevention); 3)
not receiving inpatient drug treatment; and 4) speaking
English or Spanish. Eligible clients were introduced to
the study by the site nurse. Those who were interested
received additional information and, once formal
informed consent was obtained, research assistants
conducted baseline assessments at the clinical site or
client’s home. Of 549 women referred, 65 were ineli-
gible, 68 could not be located, 114 refused to partici-
pate, and 302 (72.6% of eligible clients) were enrolled.
We randomized participants to two treatment con-
ditions: motivational interviewing (MI = 156) and
usual care (UC = 146). Participants’ responses were
assessed at baseline, 1 month after the intervention,
and 6 months postpartum.
Intervention Conditions
Motivational intervention. Women randomly assigned
to MI received an average of three home visits that
speciﬁcally employed MI [19,20] to deliver a smoking
intervention. TheMI sessions: 1) educated clients about
the impact of smoking on mothers, fetuses, and new-
borns; 2) helped clients evaluate their smoking behav-
ior; 3) helped increase self-efﬁcacy for smoking
cessation and abstinence; 4) provided information on
Figure 1 A model of the strategies for smoking
cessation and relapse prevention among preg-
nant women. BL, baseline; LY, life-year; 6 MFU,
6 months follow-up; MI, motivational interview-
ing; QALY, quality-adjusted life-year; UC, usual
care.
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reducing exposure to environmental tobacco smoke
and set goals on changes in smoking; and 5) provided
feedback about household nicotine levels. TheMI com-
ponents were tailored to each client’s stage of readiness
and MI sessions lasted 1 hour on average. MI subjects
also received self-help smoking cessation manuals.
Usual care. These women received standard prenatal
care from their health-care provider at the clinic site.
An up-to-5-minute intervention outlined the harmful
effects of smoking during and after pregnancy. Self-
help materials were also provided.
Primary cost data for interventions. All inputs con-
sumed in the interventions were measured and valued
alongside the clinical trial to enhance the reliability
and validity of intervention costs. We developed a
process-tracking form for completion at the time of
intervention and used a checklist to identify the fol-
lowing: 1) components delivered; 2) amount of time
spent with each client for intervention delivery and
follow-up; 3) materials provided; and 4) travel time
and distance. Costs collected were those necessary to
reproduce the intervention in a nonresearch setting
[18], including: 1) staff time related to intervention
delivery; 2) costs of analyzing environmental nicotine
(used in MI); 3) cost of training staff (nurses); and 4)
costs of producing self-help materials. The process
tracking system tracked staff time and distinguished
intervention time from research and evaluation time.
We did not include productivity costs [18] (work time
lost because of morbidity or mortality) or the cost of
setting up the program, but we included patient time as
a direct cost. Overhead costs were minimal and similar
in both the MI and UC groups and therefore were
excluded. All costs were reported in 1997 dollars and
updated, where necessary, using the medical care com-
ponent of the consumer price index from the Bureau of
Labor Statistics [21]. The costs of the components
were summed to obtain per participant costs.
The cost analysis was extended to the societal per-
spective by including net resource costs: 1) the interven-
tion costs described above; 2) cost savings for neonatal
intensive care, chronic medical conditions, and acute
conditions during the ﬁrst year of life; and 3) cost
savings for maternal health care (cardiovascular and
lung diseases). To be consistent with previous studies
[18] and because estimates of projected cost savings for
infants and mothers (maternal lifetime medical expen-
ditures) were obtained from the literature, these esti-
mates were included in the sensitivity analysis but
conservatively assumed to be $0 (“no savings”) in the
base case since there were no statistically signiﬁcant
differences in infant health outcomes orNeonatal Inten-
sive Care Unit (NICU) admissions between the groups.
Published estimates of net lifetime medical costs are
$6239 (discounted 1990 dollars) more for smokers
than for nonsmokers [22–24]. Published estimates that
include net smoking-attributable medical costs for neo-
natal intensive care, chronic medical conditions, and
acute conditions during the ﬁrst year of life range from
$1024 to $1228 [25] (in discounted 1996 dollars). The
base-case estimate of savings in infantmedical costswas
$0, but we used costs ranging from $1000 to $5000 in
sensitivity analyses.
Outcome Measures
Smoking status. The primary outcome measures were
smoking cessation and relapse prevention. At each
assessment, the participant was asked if she had
smoked a cigarette, even a puff, within the previous
30 days. A “quitter” smoked at baseline but not at
follow-up. A “relapse prevented” had quit smoking
within 3 months of baseline and was abstinent at
follow-up. Smoking status was veriﬁed biochemically
by collecting saliva samples for saliva cotinine analysis.
Infant health outcomes. Birth weight and postdelivery
status were assessed from medical charts.
Life-years and quality of life. Effectiveness measures
were extended to the societal perspective by using pub-
lished data and estimates [18,22,24,26–28] to convert
quit and relapse prevention rates into LYs saved and
QALYs saved. Separate estimates of life expectancy
and quality-adjusted life expectancy for female
smokers and former smokers by age group and dura-
tion of quitting were obtained from the literature
[22,23]. These estimates were based on differences in
life expectancy between ex-smokers and smokers for
each age group of women using a 20-year phase-in
period based on mortality ratios of quitters to never
smokers derived from the American Cancer Society’s
Cancer Prevention Study (CPS II) [26]. These estimates
of quality-of-life-year adjustments for women by age
[23], had been calculated using a Markov model and
the Years of Healthy Life [29] measure constructed
from questions on the annual National Health Inter-
view Survey [28]. Speciﬁc modeling assumptions used
in calculating discounted LY and QALY estimates are
reported elsewhere [23], but it should be noted that the
estimates did allow for a 35% lifetime probability of
relapse after 1 year of abstinence as recommended in a
1990 Surgeon General’s Report [26] and future ben-
eﬁts were discounted at a 3% annual rate as recom-
mended by the Panel on Cost-Effectiveness in Health
and Medicine [18]. Published estimates indicated that
female quitters and abstainers aged 25–29 years saved
1.43 LYs and 1.94 QALYs, discounted at a rate of 3%
[22,23]. We used these estimates in our analyses.
Statistical Analysis
Univariate and bivariate analyses. Univariate analysis
assessed overall sample characteristics. Bivariate
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analysis examined unadjusted relationships between
the intervention group and various factors. Chi-square
tests compared groups. Bivariate correlations between
continuous variables were analyzed with Student’s
t-test. Analysis of variance among multiple groups
evaluated differences in unadjusted mean values
between each pair of means for each group. P-values
were evaluated for each group-wise comparison. Bon-
ferroni corrections to signiﬁcance levels permitted
multiple comparisons.
Cost-effectiveness analysis. We estimated the incre-
mental cost-effectiveness of MI compared to UC by
calculating the ratio of the difference in intervention
costs to the resulting incremental beneﬁt among MI
participants compared to those receiving UC. The
analysis was performed separately for the smokers at
baseline (SC) and former smokers who had quit within
3 months of baseline (RP). The cost-effectiveness
analysis was extended to the societal perspective by
incorporating published estimates of net economic
costs and overall health consequences of smoking ces-
sation and relapse prevention (described previously).
We estimated a set of cost-effectiveness ratios, express-
ing them as net resource cost per LY gained or QALY
gained.
Sensitivity analyses. We examined the robustness of
our cost-effectiveness ratio estimates in sensitivity
analyses that varied important parameters singly, and
in combination, through clinically meaningful ranges.
Sensitivity analyses were performed on MI’s effective-
ness for smoking cessation and relapse prevention, LY
gains and quality-of-life-year weights, intervention
cost, inclusion of maternal medical cost savings, and
inclusion of cost savings for infant health care during
the ﬁrst year of life.
Results
Baseline Characteristics
Table 1 presents baseline characteristics for the 302
participants. Study groups were comparable at base-
line in terms of age, race/ethnicity (except for race
other), education, marital status, smoking status,
health insurance, and age of ﬁrst smoke. Average age
was 26 years in both groups.
Costs
The mean intervention cost per participant was $309.2
for MI versus $4.85 for UC, a difference of $304.4 (CI
$289.2–320.2). The main cost components of MI were
intervention delivery, travel time, and training, which
occurred by design. All direct program costs were in
1997 dollars.
Effectiveness
At 6 months postpartum, the two groups had similar
cessation rates (7/110 [MI] vs. 8/100 [UC]), although
the MI group had twice the relapse prevention rate as
the UC group (9/21 [MI] vs. 5/28 [UC]; P = 0.055)
(Table 2).
Cost-Effectiveness
For smoking cessation, MI cost more but provided no
additional beneﬁt compared to UC. Therefore, the
incremental cost per LY and per QALY saved from
smoking cessation was not estimated in the base case,
and MI was dominated by UC. The MI intervention
did, however, prevent relapse more effectively than
UC. The incremental cost per LY saved by relapse
prevention among MI ex-smokers compared to UC
ex-smokers was an estimated $851/LY (Table 3). The
incremental cost per QALY of preventing relapse
among MI ex-smokers compared to UC ex-smokers
was estimated at $628/QALY (Table 3).
Sensitivity Analyses
The program’s effectiveness for smoking cessation
varied from one quitter per 110 smokers to 10 quitters
per 110 smokers (baseline: 7/110). Effectiveness mea-
sured by the number of relapses prevented varied from
3 to 12 per 21 ex-smokers (baseline: 9/21). Discounted
QALYs gained varied from 0.025 to 2 (baseline
Table 1 Baseline characteristics of participants in the MI and
UC groups*
Characteristic
Women, n (%) or mean [95% CI or SE]†
Motivational intervention
(MI) (N = 156)
Usual care (UC)
(N = 146)
Age (year), mean [range] 25.6 [24.5–26.5] 25.7 [24.6–26.8]
Race/ethnicity
White 109 (70.3) 94 (64.4)
Asian/Paciﬁc Islander 1 (0.65) 0 (0.0)
Black 30 (19.4) 22 (15.1)
Hispanic 13 (8.3) 16 (11.0)
American Indian,Aleut
or Eskimo
2 (1.3) 1 (0.70)
Other 12 (7.7) 29 (19.9)‡
Education
<High school 54 (34.6) 44 (30.1)
Completed high school 57 (36.5) 67 (45.9)
Postsecondary 45 (28.9) 34 (23.3)
Married 34 (21.8) 27 (18.5)
Smoking status
Baseline smoker 132 (84.6) 113 (77.4)
Baseline nonsmoker 24 (15.4) 33 (22.6)
Smoked during previous
pregnancy
55 (72.4) 63 (80.8)
Health insurance
Major medical 39 (25.3) 41 (28.3)
Medicaid 10 (6.5) 7 (4.8)
Mass health 110 (71.4) 103 (71.0)
Other 1 (0.65) 2 (1.4)
Age of ﬁrst smoke
13 years 48 (30.8) 50 (34.3)
14–17 years 67 (43.0) 75 (51.4)
18 years 39 (25.0) 20 (13.7)*
*Percentages might not sum to 100 because of rounding.
†May not sum to group total and 100% because of rounding, missing data, or multiple
recording.
‡Statistically signiﬁcant at the P < 0.05 level compared to MI.
CI, conﬁdence interval; SE, standard error.
194 Ruger et al.
assumption: 1.94). Cost varied from $250 to $2000
per participant (baseline: $309). Maternal lifetime dis-
counted medical costs saved varied from $6000 to
$12,000 (baseline assumption: $0), and infant medical
costs saved varied from $1000 to $5000 (baseline
assumption: $0), both ranges include recent estimates
of incurred maternal and infant medical costs (noted
below) [22–25]. In two-way sensitivity analyses, MI’s
effectiveness was varied with program costs. For ces-
sation, because MI was dominated by UC in the base
case, we explored the implications of improving the
cessation effectiveness of MI on the incremental cost-
effectiveness ratios. Increasing the quit rate by 2%
eliminated UC domination of MI, with an incremental
cost per LY saved of $117,100 and cost per QALY
saved of $86,300. A 3% increase led to an incremental
cost per LY saved of $19,500 and cost per QALY saved
of $14,400 (Table 4). Increasing MI’s effectiveness for
relapse prevention by around 15% resulted in an
approximately 36% decrease in the incremental cost
per QALY ratio. Thus, cost-effectiveness ratios were
not exactly proportional to effectiveness.
When the discounted years of life or QALYs gained
from smoking cessation or relapse prevention were
assumed to be as low as 0.025, MI’s incremental cost-
effectiveness for relapse prevention reached $48,700
per LY or QALY saved. Given the baseline assump-
tions of effectiveness and the QALY/LY estimates, if
the program cost $2000 per participant, the cost-
effectiveness ratios would remain favorable, at
$5600/LY saved and $4100/QALY saved compared to
UC when relapse prevention is considered. Including
discounted expected maternal medical costs for the
remaining lifetime rendered the MI “cost saving” as
compared to UC for relapse prevention.
In two-way sensitivity analysis, MI was still rela-
tively cost-effective in comparison with UC for relapse
prevention ($23,400/LY saved and $17,300/QALY
saved) even if it cost $2000 per participant and was
less effective than the base case (5/21 vs. 9/21). For
smoking cessation, a higher level of effectiveness
(9/110 vs. 7/110) and a higher cost ($400/participant)
resulted in an incremental cost-effectiveness ratio of
$112,000/QALY.
Discussion
We examined the clinical and economic implications of
two smoking cessation and relapse prevention strate-
gies, MI and UC. The cost-effectiveness of MI for
relapse prevention compared to UC was estimated to
be $851/LY saved and $628/QALY saved. When ces-
sation was considered, MI cost more than UC but
provided no additional beneﬁt. One-way sensitivity
analysis revealed that the incremental cost-
effectiveness of MI compared to UC was $86,300/
QALY saved if 8% of smokers had quit. Including
maternal medical costs in sensitivity analysis resulted
in incremental “cost savings” for MI versus UC for
Table 2 Outcome measures for motivational intervention and
usual care
Women or infants, n (%) or mean [SD]
Motivational
intervention (MI) Usual care (UC)
Smoking cessation
Smokers at baseline 110 100
Nonsmokers at 6MPP 7 8
Smokers at 6MPP 103 92
Relapse prevention
Nonsmokers at baseline 21 28
Nonsmokers at 6MPP 9 5*
Smokers at 6MPP 12 23
Infant health outcomes (nsd)†
Birth weight (g) 3241.2 [586.0] 3321.3 [612.1]
Low birth weight
(<2500 g)
16 (59.3) 11 (40.7)
NICU/special care unit 14 (10.1) 23 (17.6)
Respiratory problems at
birth
21 (15.1) 23 (17.8)
*Borderline statistical signiﬁcance (P = 0.055) compared to MI.
†Subanalyses by smoking status at baseline and 6MPP revealed no statistically signiﬁ-
cant differences.
Statistically signiﬁcant at the P < 0.05 level compared to MI.
6MPP, 6 months postpartum; NICU, neonatal intensive care unit; SD, standard
deviation.
Table 3 Costs, LYs, QALYs, and cost-effectiveness*
Total
costs†
Total
quitter/RPs†
Total
LYs†
Total
QALYs†
D
Costs
D
Quit/RP
D
LYs
D
QALYs
ICER
$/quitter
or $/RP
$/LY
saved
$/QALY
saved
Current smokers
UC (n = 100) $5 0.08 0.11 0.16 — — — — — — —
MI (n = 110) $309 0.06 0.09 0.12 $304 -0.02 -0.02 -0.04 D‡ D‡ D‡
Recent quitters
UC (n = 28) $5 0.18 0.26 0.35 — — — — — — —
MI (n = 21) $309 0.43 0.61 0.83 $304 0.25 0.36 0.49 $1217 $851 $628
*D indicates change in.
†Costs and effects are per participant in the target population; LYs and QALYs per participant were calculated as the quotient of the number of quitters or RPs multiplied by
the LYs (1.43) and QALYs (1.94) saved per quitter/RP, respectively, and the number of participants in the target group (e.g., for UC [SC] (8 ¥ 1.43)/100 = 0.11 LYs per participant
in that group).
‡D, dominated (program is more costly, but less effective than comparator).
ICER, incremental cost-effectiveness ratio; LY, life-year; MI, motivational intervention;QALY, quality-adjusted life-year; RP, relapse prevented; SC, smoking cessation; UC, usual care.
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relapse prevention, for smoking cessation MI was
dominated by UC. In two-way sensitivity analysis, MI
was still cost-effective compared to UC for relapse
prevention ($17,300/QALY saved), if it cost $2000 per
participant and was less effective (5/21). For smoking
cessation, a higher level of effectiveness (9/110) and
higher cost ($400/participant) resulted in a higher
incremental cost-effectiveness ratio ($112,000/QALY).
In general, our analysis supports previous ﬁndings
about the economic implications of smoking cessation
programs among pregnant women, although the results
of this study are difﬁcult to compare to other work.
When Ershoff et al. [11] evaluated an intervention con-
sisting of an initial interview, smoking counseling by a
health educator, mailed self-help books, and reinforce-
ment at prenatal care visits, they found that the cost
savings for a 100,000-member Health Maintenance
Organization (HMO) was $13,432, with a net beneﬁt
of $9202 and a beneﬁt–cost ratio of 3:1. They did not
extend their analysis to the societal perspective. Assess-
ing three cessation protocols forwomen in public health
maternity clinics,Windsor et al. [9] found that 2%, 6%,
and 14% of the participants in their respective groups
stopped smoking, with costs per percentage who quit of
$104, $118, and $50, respectively. Our study produced
quit rates of 6% for MI and 8% for UC, although
differences were not statistically signiﬁcant. Marks
et al. [16] modeled the beneﬁts that would accrue from
shifting low-birth-weight infants into the normal-birth-
weight category, averting deaths attributable to prema-
turity, and avoiding the long-term costs of caring for
premature infants, concluding that the ratio of savings
to costs could be as high as 6:1. They did not, however,
separate smoking from nonsmoking attributable infant
costs. When Shipp et al. [17] modeled the break-even
cost of a smoking cessation program during pregnancy,
they obtained an estimate of around $32 per pregnant
woman. Their sensitivity analysis revealed that this cost
varied from $10 to $237, depending on the probability
of adverse outcomes in various populations. Our costs
exceed their estimates but fall within their range in real
terms. To our knowledge, studies assessing the clinical
and economic implications of relapse prevention for
pregnant women are limited.
Our study has limitations. First, we studied low-
income women in Boston; therefore, our ﬁndings
Table 4 One-way sensitivity analyses
Parameter varied
Incremental cost-effectiveness
($/LY saved)*
Incremental cost-effectiveness
($/QALY saved)*
SC RP SC RP
Baseline D† 851 D 628
Effectiveness of MI for SC (baseline 7/110)
10/110 19,500 ‡ 14,400 ‡
9/110 117,100 ‡ 86,300 ‡
8/110 D ‡ D ‡
5/110 D ‡ D ‡
1/110 D ‡ D ‡
Effectiveness of MI for RP (baseline 9/21)
12/21 D 540 D 400
10/21 D 720 D 530
8/21 D 1,050 D 780
6/21 D 2,000 D 1,500
5/21 D 3,600 D 2,600
3/21 D D D D
Discounted LYs and QALYs saved (baseline 1.43 and 1.94, respectively)
2 D 610 D 610
1 D 1,200 D 1,200
0.5 D 2,400 D 2,400
0.1 D 12,200 D 12,200
0.05 D 24,400 D 24,400
0.025 D 48,700 D 48,700
Cost of the MI program (baseline $309)
$250 D 690 D 510
$500 D 1,400 D 1,020
$1,000 D 2,800 D 2,100
$2,000 D 5,600 D 4,100
Maternal medical care cost savings (baseline $0)
$6,000 D CS D CS
$12,000 D CS D CS
Cost savings for health care of newborn at birth and during ﬁrst year of life (baseline
$0)‡
$1,000 D CS D CS
$5,000 D CS D CS
*As compared to UC, assuming UC effectiveness for SC of 8/100 and for RP of 5/28 and direct UC program costs of $4.85 per participant.
†D, MI is dominated by UC (MI is more costly and less effective than UC).
‡For infants of women who quit or remained abstinent—estimates are per participant in the target population.
LY, life-year; MI, motivational intervention; QALY, quality-adjusted life-year; RP, relapse prevention; SC, smoking cessation; UC, usual care; CS, cost saving.
196 Ruger et al.
cannot be generalized to other economic (high-income)
and geographic groups. Second, we analyzed savings in
maternal and infant medical costs but did not have
long-term morbidity and mortality data for children
related to smoking-related illnesses. Because published
estimates might be overestimates or underestimates,
we performed sensitivity analyses to determine their
impact on cost-effectiveness ratios. Third, it is difﬁcult
to know how income and pregnancy might affect
health-related quality of life and life-expectancy mea-
sures. Fourth, we did not measure some nonsmoking-
related costs and beneﬁts of MI (e.g., results from
instruction on general health and social services), since
the intervention was broader than smoking, but the
CEA did not assess those outcomes [30]. Fifth, because
of the small sample size, we may not have had enough
power to detect differences between groups on a
number of study variables. Sixth, our study may under-
estimate the importance of relapse prevention during
pregnancy because it does not consider the impact of
reducing maternal smoking during pregnancy on the
risk of nicotine dependence among offspring.
From a policy perspective, the choice of whether
to implement UC or MI will depend on available
resources, alternative uses of resources, and other con-
straints. Comparing our results with cost-effectiveness
ratios of other accepted preventive interventions dem-
onstrates that resources devoted to smoking cessation
[31] and relapse prevention during and after preg-
nancy might be worthwhile [32]. For example, cervical
cancer screening costs have been estimated to range
from $7100 (every 5 years compared to no screening)
to $175,000 (every 2 years compared to every 3 years)
per LY saved [33].
In conclusion, our analysis suggests that, among
low-income pregnant women, MI can prevent relapse
at relatively low cost whereas MI was more costly and
no more effective than UC in promoting smoking ces-
sation. Inclusion in sensitivity analyses of net medical
cost savings for infants and mothers as a result of
sustained cessation and abstinence results in more
favorable incremental cost-effectiveness ratios.
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